Home > Boards > US OTC > Biotechs >

Mymetics Corporation (MYMX)

Add MYMX Price Alert      Hide Sticky   Hide Intro
Moderator: TheHungryHippo, corpus
Search This Board: 
Last Post: 4/21/2019 11:48:40 PM - Followers: 71 - Board type: Free - Posts Today: 0






Mymetics Corporation is US registered biotechnology company with its main offices in Switzerland and the Netherlands.
Focused on developing next generation preventative vaccines for infectious diseases.
Mymetics core technology and expertise are in the use of virosomes,
lipid-based carriers containing functional fusion viral proteins in combination with rationally designed antigens and membrane proteins.

Objective: "Build small / medium size innovative R&D virosome vaccine company with strong 
partnerships, Phase II – III clinical vaccine pipeline and have optionality for M&A or sale."


Current Share Structure:

Outstanding Shares: 303.7 million (as of 01/18/2019 unchanged since 2014)
Floating Shares: 79.8 million*  (a/o 01/18/19)



Current Projects and Pipeline


Rationale and Impact of MACIVIVA

With few exceptions, commercialized vaccines are generally delivered by injection through the intramuscular or subcutaneous route.
Vaccines contain immunogens classically found within a large variety of biological compounds such as peptides, proteins, glycoproteins and sometimes carbohydrates and lipids.
These immunogens may trigger the immune system for producing antibodies and/or cytotoxic T cells for preventing the pathogen transmission or blocking and/or slowing down the disease progression.

However, these vaccines generally exist as liquid formulation that are inherently prone to physical and/or chemical modifications. The cold chain storage is still fundamental for preserving the
bioactivity of most liquid and freeze-dried vaccines. For reconstituted freeze dried vaccines, they harbor important instability and must be used within hours and kept refrigerated. Vaccine degradation generally takes place
during shipment and/or storage of liquid or lyophilized products, which may affect the immunological properties of the immunogens, with unwanted immune responses or insufficient immune protection.
There is growing evidence that solid dosage formats (e.g. powder form) for vaccines may offer several advantages over the liquid formulations, such as the prevention of molecular motion and shear-induced degradation,
and slowing down modifications and degradation reactions involving water and oxygen radicals, resulting in improved stability, enhanced shelf-life of vaccines and greatly simplified logistics.

Toward cold chain free vaccines

Today, no commercial vaccine has been developed yet under thermostable solid form (cold chain independent)
for direct nasal or oral delivery (ex. intranasal powder delivery or sublingual pills) without the need of reconstitution with a liquid.


Expertise: R&D on virosome formulations

Project responsability: Investigating and compiling the results about the physical and biochemical properties of the virosome-based vaccines obtained by spray-drying and lyophilization.

Expertise : Non-GMP and GMP virosome production, clinical development

Project responsability: Excipient selection for liquid virosomes, supervising the non-GMP and GMP manufacturing of the liquid virosomes and development of analytical methods.

Expertise: Non-GMP and GMP Spray drying

Project responsability: Identification of excipients and experimental conditions suitable for virosome spray drying, production of non-GMP and GMP powder forms for nasal and oral delivery.

Expertise: Zydis technology for fast-dissolving tablet, world leader in drug formulation and distribution

Project responsability: Identification of excipients and experimental conditions suitable for virosome lyophylization, according to the Zydis technology, non-GMP and GMP tablets for sublingual delivery.

Expertise: Ultra sensitive immunoassays development and bioanalysis based on Imperacer® (Immuno-PCR) technology.

Project responsability: Immunogenicity study in animals with spray-dried and lyophilized virosomes. Imperacer® immunoassay development and evaluation of the vaccine-induced antibody response.

Expertise: R&D, non-GMP and GMP manufacturing of API, world supplier

Project responsability: Process Development and manufacture of peptide P1, GMP-grade, including development and validation of analytical methods.


PXTHERAPEUTICS announces the successful completion of RGP41 GMP manufacturing for Mymetics  

Grenoble, France, and Epalinges, Switzerland, December 12th, 2017 – PXTherapeutics, a CDMO specializing in the development of recombinant proteins for human and animal health, is proud to announce the end of the rgp41 manufacturing campaign and batch certification for clinical application. This drug substance will be used by Mymetics to develop a new vaccine formulation, within the framework of the MACIVIVA project, sustained by the European Union’s Horizon 2020 research and innovation program and the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners. 

Rgp41 protein is one of the HIV-1 gp41 derived antigens constituting Mymetics’ HIV-1 vaccine that is anchored to the membrane surface of the virosome particle, which acts as vaccine delivery vehicle for soliciting the immune system for inducing the production of protective serum and mucosal antibodies. 

PXTherapeutics and Mymetics joined forces several years ago to work on rgp41 protein design and development of the production and purification processes of the molecule. PX teams managed to develop an efficient, scalable and GMP-compliant process. A clinical batch was produced from a scale fermentation volume of 120 L to deliver a sufficient quantity for formulation studies and clinical trials. 

Claire Untereiner, Chief Operating Officer of PXTherapeutics, commented as follows: “We are so happy to see the progress made with this molecule and to be part of this fantastic project. MACIVIVA’s objective, the development of cold-chain independent and virosome-based vaccines, responds to a real medical need, particularly in emerging countries, and is in line with PXTherapeutics’ mission, to support and accelerate the development of innovative medicines”. 

Sylvain Fleury, Chief Scientific Officer of Mymetics SA commented: “we are pleased that PXTherapeutics could address many technical challenges related to the GMP development of the recombinant rgp41 protein and achieve a production yield superior to our expectations. With this rgp41, Mymetics will further pursue the development of its HIV-1 candidate vaccine, which could be administered through various immunization routes, as a standalone product or combined with viral vectors in a prime-boost approach”. 


Vaccines are poorly accessible in developing countries

Vaccines require cold-chain storage and are often delivered by injection, which is undesirable, less safe and more expensive to administer.
Developing thermostable solid form vaccines through non-invasive routes may represent a long-term global solution to the vaccination challenge (Amorij, 2008).

Virosomes are an efficient vaccine delivery system

Virosomes are spherical, unilamellar lipid-based carriers, intercalated with functional glycoproteins to reflect the natural virus, however the lack of viral RNA means there is no risk of infection
(Figure 1). Virosomes can be tagged with different antigens and adjuvants, meaning they can be tailored to target different viruses, and offer increased immunogenicity over inactivated viruses.
Currently, virosomal influenza vaccines are only available in liquid form (Amorij, 2008).

Spray drying can produce dry powders for a range of dosage forms, including inhaled or nasal drug delivery.

A dry powder is formed when a liquid feed solution or suspension is atomised using a spray nozzle, and rapidly dried using hot air. However, while the drying process is gentle due to evaporative cooling,
there is still the potential to stress and inactivate vaccine components. It has been found that subunit and live-attenuated vaccines (and other delicate molecules such as proteins)
can be protected during processing b by incorporating them in an amorphous sugar matrix, which also offers longer term stability during storage (Kanojia, 2016).

A method has been developed to produce a powder form of virosome based influenza vaccine using spray-drying.

Formulations have been optimised for oral and nasal delivery.

Advantages of Virosomal Drug Delivery

         Virosomal technology is approved by the FDA for use in humans, and has a high safety profile
         Virosomes are biodegradable, biocompatible, and non-toxic12
         No disease-transmission risk
         No autoimmunogenity or anaphylaxis10
         Broadly applicable with almost all important drugs (anticancer drugs, proteins, peptides, nucleic acids, antibiotics, fungicides)
         Enables drug delivery into the cytoplasm of target cell
         Promotes fusion activity in the endolysosomal pathway
         Protects drugs against degradation


Virosomal Structure and Modifications

Image result for influenza virosome images

Figure 1: Virosomes are reconstituted influenza virus envelopes devoid of inner core and genetic information
Virosomes are spherical unilamellar vesicles with a mean diameter of around 150 nm. Influenza virus is most commonly used for virosome production. Virosomes cannot replicate but are pure fusion-active vesicles. In contrast to liposomes, vorosomes contain functional viral envelope glycoproteins: influenza virus hemagglutinin (HA) and neuraminidase (NA) are intercalated within the phospholipid bilayer membrane (Figure 1). Further characteristics of virosomes depend on the choice of bilayer components. Virosomes can be optimized for maximal incorporation of the drug, or for the best physiological effect by modifying the content or type of membrane lipids used. It is even possible to generate carriers for antisense-oligonucleotides or other genetic molecules, depending on whether positively or negatively loaded phospholipids are incorporated into the membrane. Various ligands, such as cytokines, peptides, and monoclonal antibodies (MAbs) can be incorporated into the virosome and displayed on the virosomal surface. Even tumor-specific monoclonal antibody fragments (Fab) can be linked to virosomes to direct the carrier to selected tumor cells.1,11

Intellectual  Property

WO/1999/025377 (GP41 mutee) Method for obtaining vaccines for preventing the pathogenic effects related to a retroviral infection Mymetics Corp. Expiration date: November 16, 2018
WO/2005/010033 (GP41 ter) New soluble and stabilized trimeric form of GP 41 polypeptide Mymetics Corp. Expiration date: July 28, 2024
WO/2007/099446 (Virosome-P1) Virosome-like vesicles comprising gp41 - derived antigens Mymetics Corp. + INSERM + Pevion Expiration date: January 3, 2027

US/61/202 215 (GP41 4th gen) Mymetics Corp. Expiration date: February 5, 2029
US/61/202 219 (Splitting GP41) Mymetics Corp. Expiration date: February 5, 2029
WO/2004/106366 (UK39) Methods for synthetizing conformationally constrained peptides, peptidomimetics and use of such peptidomimetics as synthetic vaccines Mymetics Corp. Expiration date: June 1, 2024
WO/2004/078099 (AMA49) Compositions and methods for the generation of immune response against Malaria Mymetics Corp. Expiration date: March 2, 2023
WO/2004/045641 (APRECS) Antigen-complexes Bestewil BV Expiration date: November 19, 2023
WO/2004/110486 (Lipopeptide) Functionally reconstituted viral membranes containing adjuvant Bestewil BV Expiration date: June 17, 2024
WO/2004071492 (DCPC) Virosome-like particles Bestewil BV Expiration date: December 2, 2023
  [Viruses that can be applied and used in the formation of the virosome-like-particles according to the invention can be derived from all sorts of viruses, non-limiting examples of     such viruses being: Retroviridae such as Human Immunodeficiency virus (HIV); rubellavirus; paramyxoviridae such as parainfluenza viruses, measles, mumps, respiratory syncytial virus, human metapneumovirus; flaviviridae such as yellow fever virus, dengue virus, Hepatitis C Virus (HCV), Japanese Encephalitis Virus (JEV), tick-borne encephalitis, St. Louis encephalitis or West Nile virus; Herpesviridae such as Herpes Simplex virus, cytomegalovirus, Epstein-Barr virus; Bunyaviridae; Arenaviridae; Hantaviridae such as Hantaan; Coronaviridae; Papovaviridae such as human Papillomavirus; Rhabdoviridae such as rabies virus. Coronaviridae such as human coronavirus; Alphaviridae, Arteriviridae, filoviridae such as Ebolavirus, Arenaviridae, poxyiridae such as smallpox virus, and African Swine Fever virus.]  








Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MYMX News: Annual Report (10-k) 03/28/2019 08:35:35 AM
MYMX News: Quarterly Report (10-q) 11/13/2018 04:48:34 PM
PlusOneCoin Top Posts
No plusone'd posts yet. Be the first!
#9228  Sticky Note MYMX VACCINE COMPANY OVERVIEW TheHungryHippo 10/06/18 01:28:07 PM
#5685  Sticky Note Copy of MACIVIVA Presentation at World Vaccine Congress corpus 01/09/18 12:36:16 PM
#13219   Anergis needs Mymetics!!! The video says it all! The TheHungryHippo 04/21/19 11:48:40 PM
#13218   eTheRNA Trimix Poster twitter: Phosphene 04/20/19 08:09:38 PM
#13217   Uncle Bill and Aunt Melinda: "These monoclonal antibodies Phosphene 04/20/19 08:04:22 PM
#13216   Happy Easter to all. Phosphene 04/20/19 07:59:48 PM
#13215   Happy easter dudes. Hopefully Kempers tells us whats TheHungryHippo 04/18/19 05:02:29 PM
#13214   $MYMX COULD BE THE BIGGEST MERGER IN ALL TheHungryHippo 04/18/19 12:44:03 PM
#13213   dont understand how nite has fn shares to TheHungryHippo 04/18/19 12:21:21 PM
#13212   40% of the time it works all of Staypositive1 04/18/19 08:19:24 AM
#13211   GSK and partners https://www.kff.org/news-summary/gsk-to-begin-pilot-program-fo Staypositive1 04/18/19 05:19:17 AM
#13210   Bristol-Myers Squibb (BMY), Eli Lilly (LLY) and Pfizer bow-tie 04/17/19 10:54:41 PM
#13209   Im ready to congratulate Mr. Kempers! TheHungryHippo 04/17/19 05:09:14 PM
#13208   MYMETICS could be merging with Anergis. TheHungryHippo 04/17/19 05:08:12 PM
#13207   IT'S A "TURN AROUND STORY" IN THE MAKING BOYS! TheHungryHippo 04/17/19 05:00:45 PM
#13206   $MYMX UP 1.3% TWO GREEN DAYS IN A ROW! TheHungryHippo 04/17/19 04:59:48 PM
#13205   I haven't seen a chance Work Harder 04/17/19 02:58:12 PM
#13204   Will Kempers redeem himself? TheHungryHippo 04/17/19 02:56:14 PM
#13203   Sssshhh b/c it's Work Harder 04/17/19 02:53:52 PM
#13202   F- man. where the F news man. TheHungryHippo 04/17/19 02:34:46 PM
#13201   Anergis S.A. bow-tie 04/16/19 10:28:21 PM
#13200   Sten Verland, PhD MSc bow-tie 04/16/19 10:06:58 PM
#13199   Hang in there shun Work Harder 04/16/19 04:37:49 PM
#13198   Unbelievable. Up 5%....what an absolute turnaround. Staypositive1 04/16/19 04:24:24 PM
#13197   Yep, Puddles seeed Work Harder 04/16/19 04:14:30 PM
#13196   That make up left a picture on the Staypositive1 04/16/19 04:13:01 PM
#13195   It's starting to look like Work Harder 04/16/19 04:06:37 PM
#13194   You suggesting he not Work Harder 04/16/19 03:59:01 PM
#13193   Ronald "cant get it done" Kempers Ronald "not a Staypositive1 04/16/19 03:57:12 PM
#13192   With the way NOVARTIS is behaving Work Harder 04/16/19 03:49:09 PM
#13191   BEOB about to make it rain Work Harder 04/16/19 02:47:00 PM
#13190   Heck yeow, burn the house down Work Harder 04/16/19 01:50:07 PM
#13189   Im expecting news to reach the national media Staypositive1 04/16/19 01:49:08 PM
#13188   Bullish MACD Crossover Work Harder 04/16/19 01:20:33 PM
#13187   You'll know when BEOB Work Harder 04/16/19 12:49:12 PM
#13186   Maybe this is the "end game" for mymetics! Staypositive1 04/16/19 12:40:04 PM
#13185   Geoffrey Lamb bow-tie 04/16/19 11:33:55 AM
#13184   Jacques-François Martin is affiliated with Parteurop, GAVI Alliance, bow-tie 04/16/19 11:20:31 AM
#13183   While sipping Work Harder 04/16/19 10:47:28 AM
#13182   I'm tired of hearing Kemper's playing Video games bow-tie 04/16/19 10:46:12 AM
#13181   VC for Ceo, it's not like Kempers Work Harder 04/16/19 10:44:01 AM
#13180   BEOP is BEOB Work Harder 04/16/19 10:42:04 AM
#13179   If I was Ulick I would kick Kemper's bow-tie 04/16/19 10:41:12 AM
#13178   If I was Ulick I would kick Kemper's bow-tie 04/16/19 10:41:11 AM
#13177   GM, BEOP Work Harder 04/16/19 10:11:04 AM
#13176   Glad someone's doing well. Phosphene 04/15/19 11:21:51 PM
#13175   Catalent Buys Paragon for $1.2 Billion to Build bow-tie 04/15/19 09:36:36 PM
#13174   LOL, no escaping it Work Harder 04/15/19 09:11:47 PM
#13173   Yes, Sad! Kemper's has never had it together, bow-tie 04/15/19 09:08:55 PM
#13172   A Kempers like Work Harder 04/15/19 09:00:46 PM
#13171   what's going on? bow-tie 04/15/19 08:58:33 PM
#13170   Ok, I see where this is coming from Work Harder 04/15/19 08:52:45 PM